Thrombomodulin Influences the Survival of Patients with Non-Metastatic Colorectal Cancer Through Epithelial-To-Mesenchymal Transition (EMT)

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2016 Aug 12

PMID 27512995

Citations 11

Authors

Yu-Jia Chang

Ya-Wen Cheng

Ruo-Kai Lin

Chi-Chou Huang

William Tzu-Liang Chen

Tao-Wei Ke

Po-Li Wei

Affiliations

Soon will be listed here.

Abstract

Background: Treatment resistance and metastasis are the major causes of death among patients with colorectal cancer (CRC). Approximately 20% of surgically treated patients ultimately develop metastases during the follow-up period. Currently, the TNM system is the only available prognostic test. Therefore, the identification of new markers for CRC remains important. Thrombomodulin (TM), a glycoprotein, is involved in angiogenesis and has been linked to many malignant diseases. However, the function of TM in CRC remains unclear.

Methods: A total of 170 patients with CRC participated in this study. TM expression was analyzed via immunohistochemistry. Univariate (Kaplan-Meier) analysis was used to analyze patient outcomes, including overall survival (OS) and disease-free survival (DFS). TM expression was manipulated using shRNA or an overexpression system. Transwell migration assays, wound healing migration assays, and the xCELLigence biosensor system were used to detect cell proliferative and migratory capacities.

Results: TM expression in the tumor tissues significantly and positively correlated with the DFS and OS of non-metastatic patients with CRC (ps = 0.036 and 0.0218, respectively). Suppression of TM expression increased the proliferation and migration of DLD-1 cells. TM overexpression reduced the cells' proliferative and migratory capacities. Cyclooxygenase (COX)-2 expression was up-regulated following TM silencing. Furthermore, the association between the migration of colon cancer cells and the levels of TM and epithelial-to-mesenchymal transition (EMT) markers (fibronectin, vimentin and ezrin) was confirmed in HT29 and DLD-1 cells.

Conclusions: Our study demonstrates that patients with non-metastatic CRC display low TM expression in their tumors and exhibit reduced DFS and OS. The enhanced expression of mesenchymal markers and COX-2 may be involved in the mechanisms that underlie recurrence in patients with cancer displaying low TM expression.

Citing Articles

Haemostatic Gene Expression in Cancer-Related Immunothrombosis: Contribution for Venous Thromboembolism and Ovarian Tumour Behaviour.

Tavares V, Savva-Bordalo J, Rei M, Liz-Pimenta J, Assis J, Pereira D Cancers (Basel). 2024; 16(13).

PMID: 39001418 PMC: 11240748. DOI: 10.3390/cancers16132356.

Identification of angiogenesis-related genes in diabetic foot ulcer using machine learning algorithms.

Wang X, Meng L, Zhang J, Zou L, Jia Z, Han X Heliyon. 2023; 9(12):e23003.

PMID: 38076120 PMC: 10703730. DOI: 10.1016/j.heliyon.2023.e23003.

Crosstalk between Circulating Tumor Cells and Plasma Proteins-Impact on Coagulation and Anticoagulation.

Wang Y, Schneider S, Gorzelanny C Cancers (Basel). 2023; 15(11).

PMID: 37296987 PMC: 10252011. DOI: 10.3390/cancers15113025.

The Role of Thrombomodulin in Estrogen-Receptor-Positive Breast Cancer Progression, Metastasis, and Curcumin Sensitivity.

Huang C, Wei P, Hossain Prince G, Batzorig U, Lee C, Chang Y Biomedicines. 2023; 11(5).

PMID: 37239055 PMC: 10216190. DOI: 10.3390/biomedicines11051384.

Thrombomodulin expression impacts the recurrence and long-term survival in pancreatic cancer.

Sugano H, Shirai Y, Sato S, Hamatani S, Hamura R, Taniai T Ann Gastroenterol Surg. 2021; 5(4):567-574.

PMID: 34337305 PMC: 8316731. DOI: 10.1002/ags3.12447.

References

Lager D, Callaghan E, Worth S, Raife T, Lentz S . Cellular localization of thrombomodulin in human epithelium and squamous malignancies. Am J Pathol. 1995; 146(4):933-43. PMC: 1869252. View

Eriksson J, Dechat T, Grin B, Helfand B, Mendez M, Pallari H . Introducing intermediate filaments: from discovery to disease. J Clin Invest. 2009; 119(7):1763-71. PMC: 2701876. DOI: 10.1172/JCI38339. View

Bocca C, Bozzo F, Cannito S, Parola M, Miglietta A . Celecoxib inactivates epithelial-mesenchymal transition stimulated by hypoxia and/or epidermal growth factor in colon cancer cells. Mol Carcinog. 2011; 51(10):783-95. DOI: 10.1002/mc.20846. View

Yang A, Fan F, Camp E, Van Buren G, Liu W, Somcio R . Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines. Clin Cancer Res. 2006; 12(14 Pt 1):4147-53. DOI: 10.1158/1078-0432.CCR-06-0038. View

Chang Y, Chen W, Huang C, Liu H, Wei P . Glucose-regulated protein 78 (GRP78) regulates colon cancer metastasis through EMT biomarkers and the NRF-2/HO-1 pathway. Tumour Biol. 2014; 36(3):1859-69. DOI: 10.1007/s13277-014-2788-x. View

Raife T, Lager D, Madison K, Piette W, Howard E, Sturm M . Thrombomodulin expression by human keratinocytes. Induction of cofactor activity during epidermal differentiation. J Clin Invest. 1994; 93(4):1846-51. PMC: 294263. DOI: 10.1172/JCI117171. View

Eckes B, Dogic D, Wang N, Maniotis A, Ingber D, Merckling A . Impaired mechanical stability, migration and contractile capacity in vimentin-deficient fibroblasts. J Cell Sci. 1998; 111 ( Pt 13):1897-907. DOI: 10.1242/jcs.111.13.1897. View

Tai C, Chin-Sheng H, Kuo L, Wei P, Lu H, Chen H . Survivin-mediated cancer cell migration through GRP78 and epithelial-mesenchymal transition (EMT) marker expression in Mahlavu cells. Ann Surg Oncol. 2011; 19(1):336-43. DOI: 10.1245/s10434-011-1692-5. View

Sato N, Funayama N, Nagafuchi A, Yonemura S, Tsukita S . A gene family consisting of ezrin, radixin and moesin. Its specific localization at actin filament/plasma membrane association sites. J Cell Sci. 1992; 103 ( Pt 1):131-43. DOI: 10.1242/jcs.103.1.131. View

10.

Liu P, Tsai J, Chiu C, Hwang J, Chou S, Wang C . Decreased expression of thrombomodulin is correlated with tumor cell invasiveness and poor prognosis in nonsmall cell lung cancer. Mol Carcinog. 2010; 49(10):874-81. DOI: 10.1002/mc.20663. View

11.

Esmon C, Esmon N, HARRIS K . Complex formation between thrombin and thrombomodulin inhibits both thrombin-catalyzed fibrin formation and factor V activation. J Biol Chem. 1982; 257(14):7944-7. View

12.

Huang C, Batzorig U, Cheng W, Huang M, Chen W, Wei P . Glucose-regulated protein 94 mediates cancer progression via AKT and eNOS in hepatocellular carcinoma. Tumour Biol. 2015; 37(4):4295-304. DOI: 10.1007/s13277-015-4254-9. View

13.

Sierko E, Wojtukiewicz M, Zawadzki R, Zimnoch L, Kisiel W . Expression of protein C (PC), protein S (PS) and thrombomodulin (TM) in human colorectal cancer. Thromb Res. 2009; 125(3):e71-5. DOI: 10.1016/j.thromres.2009.09.011. View

14.

Batlle E, Sancho E, Franci C, Dominguez D, Monfar M, Baulida J . The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat Cell Biol. 2000; 2(2):84-9. DOI: 10.1038/35000034. View

15.

Friedl P, Wolf K . Tumour-cell invasion and migration: diversity and escape mechanisms. Nat Rev Cancer. 2003; 3(5):362-74. DOI: 10.1038/nrc1075. View

16.

Cavallaro U, Christofori G . Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nat Rev Cancer. 2004; 4(2):118-32. DOI: 10.1038/nrc1276. View

17.

BRETSCHER A . Purification of an 80,000-dalton protein that is a component of the isolated microvillus cytoskeleton, and its localization in nonmuscle cells. J Cell Biol. 1983; 97(2):425-32. PMC: 2112519. DOI: 10.1083/jcb.97.2.425. View

18.

Cano A, Perez-Moreno M, Rodrigo I, Locascio A, Blanco M, del Barrio M . The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol. 2000; 2(2):76-83. DOI: 10.1038/35000025. View

19.

Kirane A, Toombs J, Larsen J, Ostapoff K, Meshaw K, Zaknoen S . Epithelial-mesenchymal transition increases tumor sensitivity to COX-2 inhibition by apricoxib. Carcinogenesis. 2012; 33(9):1639-46. PMC: 3514897. DOI: 10.1093/carcin/bgs195. View

20.

Ruers T, Bleichrodt R . Treatment of liver metastases, an update on the possibilities and results. Eur J Cancer. 2002; 38(7):1023-33. DOI: 10.1016/s0959-8049(02)00059-x. View